Trials / Completed
CompletedNCT02244294
FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)
A Two Phase, Double-blinded, Randomized, Parallel Group Design, Multicenter Study of FLOMAX® Capsules, 0.4 mg Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 176 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
To establish whether the administration of FLOMAX® improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention and to determine whether spontaneous voiding is maintained over the course of six months of active treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FLOMAX® capsules | |
| DRUG | Placebo capsules |
Timeline
- Start date
- 2001-03-01
- Primary completion
- 2005-06-01
- First posted
- 2014-09-19
- Last updated
- 2014-09-19
Source: ClinicalTrials.gov record NCT02244294. Inclusion in this directory is not an endorsement.